(Q37979277)

26 August 2017

title

Obinutuzumab for the treatment of lymphoproliferative disorders (English)

1 reference

26 August 2017

Carolyn Owen

1

1 reference

26 August 2017

Douglas A Stewart

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

28 January 2012

1 reference

Expert Opinion on Biological Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

343-351

1 reference

Mechanisms of killing by anti-CD20 monoclonal antibodies.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

The future of CD20 monoclonal antibody therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

Rituximab-induced interstitial lung disease: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.657622

10.1517/14712598.2012.657622

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference